Filing Flows

Filing Flows › Companies › Camp4 Therapeutics › Cash flow

Camp4 Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$8.9M in Q3 2026 · −$26.4M over twelve months

Operating cash flow−$8.2M
Capital spending−$740K
Free cash flow−$8.9M

Analysis

In Q3 2026, Camp4 Therapeutics generated −$8.2M of operating cash flow and spent $740K on capital projects, leaving free cash flow of −$8.9M. That is $2.3M more than in Q3 2025 (−$11.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$25.5M; the largest uses were operating cash flow ($25.5M), capital spending ($869K), net borrowing (+) / repaid (−) ($18K); besides operations, cash came from shares issued ($44.0M), other financing ($31.7M); the cash balance rose by $49.3M.

Operating cash flow was −$8.2M against net income of −$29.0M. The largest differences: accrued liabilities +$3.1M, stock-based pay +$2.0M, deferred revenue −$1.8M.

Free cash flow

Camp4 Therapeutics: free cash flow by quarterCamp4 Therapeutics: free cash flow by quarter−$11.6MQ4 2024−$14.6MQ1 2025−$10.3MQ2 2025−$11.2MQ3 2025$6.3MQ4 2025−$11.0MQ1 2026−$12.8MQ2 2026−$8.9MQ3 2026
Operating cash flow less capital spending.
Camp4 Therapeutics: operating cash flow against capital spendingCamp4 Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$11.3M$263KQ4 2024−$14.3M$279KQ1 2025−$10.3M$0Q2 2025−$11.2M$0Q3 2025$6.3M$0Q4 2025−$11.0M$0Q1 2026−$12.7M$129KQ2 2026−$8.2M$740KQ3 2026
Latest (Q3 2026): Operating cash flow −$8.2M, Capital spending $740K.

Capital allocation, year by year

Camp4 Therapeutics: where the cash came from (up) and went (down), by fiscal yearCamp4 Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2023: Operating cash flow −$44.2MFY2023: Net borrowing −$322KFY2023: Shares issued $185KFY2023: Capital spending −$678K$185KFY2023FY2024: Operating cash flow −$45.6MFY2024: Net borrowing −$364KFY2024: Shares issued $76.5MFY2024: Capital spending −$441K$76.5MFY2024FY2025: Operating cash flow −$29.6MFY2025: Net borrowing −$111KFY2025: Shares issued $57.5MFY2025: Asset sales $36KFY2025: Capital spending −$279K$57.6MFY2025
Over these 3 years operating cash flow totalled −$119M; the largest uses were operating cash flow ($119M) and capital spending ($1.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$125M
Debtnone
Net cash$125M
Cash runway4.7 years

Camp4 Therapeutics is burning cash: its operations consume cash, a free cash flow of −$26.4M a year at the current rate against $125M of cash and investments: a runway of about 4.7 years before any new financing.

Where the cash came from and went

Camp4 Therapeutics: sources (+) and uses (−) of cash, Q3 2026Camp4 Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other financing$47.0MCash drawn (+) / kept (−)−$38.1MOperating cash flow−$8.2MCapital spending−$740K
Camp4 Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Camp4 Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)−$49.3MShares issued$44.0MOther financing$31.7MOperating cash flow−$25.5MCapital spending−$869KNet borrowing (+) / repaid (−)−$18K

From profit to cash

Camp4 Therapeutics: net income to operating cash flow, Q3 2026Camp4 Therapeutics: net income to operating cash flow, Q3 2026Net income−$29.0MDepreciation & amortization$523KStock-based pay$2.0MPayables−$346KAccrued liabilities$3.1MDeferred revenue−$1.8MPrepaid and other assets$614KOperating cash flow−$8.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$8.2M−$740K——−$38.1M−$8.9M
Q2 2026−$12.7M−$129K——$12.8M−$12.8M
Q1 2026−$11.0M———$10.9M−$11.0M
Q4 2025$6.3M—−$18K$28.6M−$34.9M$6.3M
Q3 2025−$11.2M—−$14K$29.0M−$36.2M−$11.2M
Q2 2025−$10.3M—−$43K—$10.3M−$10.3M
Q1 2025−$14.3M−$279K−$36K—$14.7M−$14.6M
Q4 2024−$11.3M−$263K−$96K$76.4M−$61.5M−$11.6M

Camp4 Therapeutics: income statement and cash flow

Camp4 Therapeutics, Q3 2026: revenue $1.9M (+139% year over year), operating margin -738.8%. The chart follows the revenue to costs, profit and cash.

Camp4 Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.